Zastumotide

DB14926InvestigationalVaccines

Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell...

Mechanism: Pharmacologically active on Melanoma-associated antigen 3
Curator reviewed
Also known as: Astuprotimut R · Astuprotimut-R
Code names: GSK1203486A · GSK1572932A · GSK2132231A

Resolves to

Compound

UNII50I23C5UORCAS949885-73-8

Targets

P43357MAGEA3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zastumotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account